Epizyme Inc (NASDAQ:EPZM) has priced its underwritten public offering of 56.7 million shares at $1.50 per share for gross proceeds of $85 million.
- The offer price represents a discount of almost 21% from the last close price of $1.90 on Wednesday.
- Underwriters have an option to purchase up to an additional 8.5 million shares.
- Epizyme will use the proceeds to fund the global development & commercialization of tazemetostat, Phase 1/1b trial of EZM0414, the discovery & identification of additional product candidates, and fund initiatives to accelerate commercial adoption of TAZVERIK.
- Earlier this month, the Company posted preliminary Tazverik (tazemetostat) sales of $11.2 million - 11.7 million in Q4 FY21 and $30.6 million - 31.1 million in FY21.
- The offering is expected to close by January 31.
- Price Action: EPZM shares are down 30.5% at $1.32 during the premarket session on the last check Thursday.
